111P - BMI effect prognostic features of breast cancer treatments
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Breast Cancer, Locally Advanced
Cancer Aetiology, Epidemiology, Prevention
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix30-ix34. 10.1093/annonc/mdw576|
M.I. Hojouj, I. Bondarenko
The (BMI) on the prognosis of metastatic breast cancer (MBC) has not been explored so far. Aim of this retrospective study is to evaluate the relation between patients’ Breast cancer (BC) to BMI and the prognosis of treatment.
The study included 143 patients with MBC between the ages of 30 and 76 (57,6 ± 1) yrs of age who were treated according to our clinic from 2006-2014. The main condition for selection was the treatment of MBC at the time of analysis. All patients were evaluated according to the following data: stage of the disease, age and BMI at the time of diagnosis, the size, histological type and degree of differentiation of the tumor and the presence of regional lymph nodes (RLN) metastases.Tumor size was evaluated after measuring its maximal diameter and distributed in accordance with the International TNM-classification . The absence of menstruation in patients over 1 year up to the moment of diagnosis was regarded as menopause. T. BMI is calculated by the formula:I = m h2, where m - body weight (kg) h -those with a BMI
1. In this retrospective study, among 108 patients with breast cancer, 44% were identified with excess body weight, and 31% - of various obesity degree. 25% Patients with normal BMI. 2. Patients with a BMI 30 kg/m2, 11% more often associated with metastatic RLN, which is anindirect sign of a higher metastatic potentials. 4. Patients with normal BMI had significantly longer overall survival (OS) and disease-free survival (DFS) than patients with intermediate or obese BMI in pairwise comparisons adjusted for other factors, But this fact is preliminary and requires further study.
This retrospective investigation our patient I–VI demonstrates that BMI is an independent prognostic factor in patients with BC. We have supporting evidence that obese BMI represents a poor risk feature for outcome, especially in pre-/perimenopausal patients.
Clinical trial indentification
October 2015, UAE
Legal entity responsible for the study
All authors have declared no conflicts of interest.